EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Adverse Drug–Drug Interaction Between Phenobarbital and Fluconazole in Two Dogs

Maria Jaramillo, Alejandra Mondino iD, Michael Court iD, Melissa J Lewis iD, Natasha J Olby iD, Karen R Muñana iD

Journal of Veterinary Internal Medicine · 2025

DOI: 10.1111/jvim.70190 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Veterinary Internal Medicine, 2025. Verfasst von Maria Jaramillo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Fluconazole, Phenobarbital, Dog Diseases, Antifungal Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Emma's Fund of the North Carolina Veterinary Medical Foundation, Emma’s Fund of the North Carolina Veterinary Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenobarbital (PB) is an antiseizure medication widely used in dogs that is metabolized by hepatic cytochrome P450 (CYP) enzymes. Fluconazole, a commonly prescribed antifungal medication, inhibits several CYP isoenzymes and can impair PB metabolism. Genetic polymorphisms such as the CYP2C41 gene deletion can alter CYP activity and influence drug interactions, although not well characterized in dogs. We describe two epileptic dogs on chronic PB treatment that developed marked sedation and ataxia, and increased serum PB concentrations after receiving fluconazole. Both dogs were homozygous for the CYP2C41 deletion. Discontinuation of fluconazole resulted in decreased PB concentrations and resolution of clinical signs. These findings suggest fluconazole can inhibit PB metabolism, leading to clinically relevant toxicity, and this interaction does not require CYP2C41 enzyme expression. Monitoring PB concentrations during fluconazole co-administration is advised. Further characterization of the role of CYP enzymes in PB metabolism in dogs is needed to better predict drug interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazolePhenobarbitalDog DiseasesAntifungal AgentsAnticonvulsantsAnimalsDogsDrug InteractionsMaleFemaleCytochrome P-450 Enzyme SystemEpilepsy

Stichwörter der Autor:innen

CYP2C41antiseizure medicationcaninecytochrome P450epilepsyhepatotoxicity

Substanzen

FluconazolePhenobarbitalAntifungal AgentsAnticonvulsantsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
  • Comparative Pharmacogenomics Laboratory, Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.

ORCID-Profile: Alejandra Mondino, Michael Court, Melissa J Lewis, Natasha J Olby, Karen R Muñana

Förderung

  • Emma's Fund of the North Carolina Veterinary Medical Foundation
  • Emma’s Fund of the North Carolina Veterinary Medical Foundation

Zitieren

APA

Jaramillo, M., Mondino, A., Court, M., Lewis, M. J., Olby, N. J., & Muñana, K. R. (2025). Adverse Drug–Drug Interaction Between Phenobarbital and Fluconazole in Two Dogs. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70190

Vancouver

Jaramillo M, Mondino A, Court M, Lewis MJ, Olby NJ, Muñana KR. Adverse Drug–Drug Interaction Between Phenobarbital and Fluconazole in Two Dogs. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70190

BibTeX
@article{Jaramillo2025,
  author = {Jaramillo, Maria and Mondino, Alejandra and Court, Michael and Lewis, Melissa J and Olby, Natasha J and Muñana, Karen R},
  title = {Adverse Drug–Drug Interaction Between Phenobarbital and Fluconazole in Two Dogs},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  doi = {10.1111/jvim.70190}
}
Kostenlos starten →